From Lasers to Shape-Shifting Polymers: New Weapons Against the Silent Leak That Threatens Aneurysm Repairs

Every year, hundreds of thousands of patients with abdominal aortic aneurysms undergo endovascular aneurysm repair, or EVAR, a minimally invasive procedure in which a fabric-lined metal stent graft is threaded through the arteries and deployed inside the weakened aorta. The procedure has become the preferred treatment worldwide because it dramatically reduces perioperative morbidity and mortality compared with open surgery. Yet its Achilles heel is a complication that most patients have never heard of: the endoleak. Blood finds a way around or through the stent graft and continues to pressurize the aneurysm sac, undermining the very purpose of the repair. Endoleaks occur in up to 30 percent of patients after EVAR, and among them, type II endoleaks—driven by retrograde flow from collateral vessels such as the inferior mesenteric and lumbar arteries—account for roughly 10 to 20 percent of cases.

For years, type II endoleaks were dismissed as largely benign quirks of the healing process. Many resolve spontaneously, and rupture associated with an isolated type II leak is uncommon. But persistent leaks can drive aneurysm sac expansion, rupture, or the need for secondary interventions, and aneurysm sac expansion after EVAR has been independently associated with late mortality. A new narrative review published in Frontiers in Cardiovascular Medicine by Krzysztof Pietrzak, Maciej Koperski, Klaudia Gutowska, and Piotr Terlecki takes stock of a rapidly evolving treatment landscape, moving beyond the traditional embolization methods that have dominated practice for two decades and spotlighting three emerging techniques: transcaval embolization, laser-assisted transgraft embolization, and prophylactic sac embolization with shape memory polymers.

The conventional playbook begins with surveillance. Contemporary guidelines from the Society for Vascular Surgery recommend monitoring type II endoleaks without aneurysm expansion and suggest treatment only when sac growth occurs, with an increase of at least 5 millimeters considered clinically relevant. The 2024 European Society for Vascular Surgery guidelines adopted an even more conservative threshold, recommending secondary intervention when sac growth reaches 10 millimeters compared with baseline or the smallest diameter recorded during follow-up, provided alternative causes such as type I or III endoleaks have been excluded. Both guidelines emphasize sac enlargement rather than the mere presence of a leak as the principal indication for treatment, a distinction the review authors argue is critical because technical elimination of endoleak flow does not invariably translate into durable sac stabilization.

When intervention is warranted, the two most established endovascular techniques are transarterial embolization and direct sac puncture via the translumbar approach. Transarterial embolization involves selective catheterization of the feeding artery—most commonly the inferior mesenteric artery or lumbar arteries—through tortuous collateral pathways, followed by deployment of coils, glue, Onyx, or gelfoam. Recent advances in imaging have refined the technique: cone-beam CT with three-dimensional image fusion allows more precise visualization of the endoleak nidus, and in a series of 37 patients, fusion-guided treatment achieved 95 percent immediate technical success and 88 percent success at one year, with significantly reduced procedure time and contrast use. Still, technical success rates for transarterial embolization vary widely from 50 to 90 percent, and recurrence rates remain high, with up to 30 percent of patients requiring repeat interventions.

Direct sac puncture offers an alternative when arterial access fails. Under CT or fluoroscopic guidance, a spinal needle is advanced through the back into the aneurysm sac, allowing direct embolization of the endoleak cavity with coils, thrombin, glue, or Onyx. Comparative studies suggest translumbar access achieves higher technical success and lower recurrence rates than the transarterial route, albeit with slightly increased procedural complexity. But the approach carries its own risks, including retroperitoneal hemorrhage, injury to surrounding organs, and patient discomfort from the prone position. Neither conventional technique directly addresses the underlying risk of recurrent collateral flow, which may explain why persistent type II endoleaks remain common even after technically successful embolization. These limitations have spurred interest in more creative routes into the aneurysm sac.

The first of the novel techniques, transcaval embolization, exploits the anatomic proximity of the inferior vena cava to the abdominal aortic aneurysm sac. Originally developed as a salvage option, the procedure involves percutaneous femoral venous access followed by transvenous catheter navigation into the cava, where the aneurysm sac is accessed through the vessel wall with either a mechanical needle or, more recently, a chronic total occlusion guidewire electrified with electrocautery to create a controlled fenestration. Once access is confirmed, embolic agents including detachable coils, Onyx, thrombin, or shape memory materials are deployed to occlude the flow channel and promote thrombosis. Intravascular ultrasound and intracardiac echocardiography allow real-time imaging of the aortic wall, enhancing puncture accuracy. A 2022 systematic review including 117 patients across 8 studies reported a pooled technical success rate of 91.4 percent, with a persistent endoleak rate of only 12.8 percent during a mean follow-up of 12 months, and one institutional series described a 100 percent access success rate using an electrified wire and liquid embolics with no procedural mortality.

Transcaval embolization is not without limits, however. Steerability of the catheter across the cava-aorta interface remains a challenge, and selective cannulation of outflow vessels was successful in only 16 percent of cases in one series. Rare but serious complications such as aortic-caval fistula formation or sac infection have been reported. The second novel approach, laser-assisted transgraft embolization, takes an entirely different route: it perforates the fabric of the stent graft itself using a 2.3-millimeter excimer laser catheter, creating a fenestration through which target vessels are selectively embolized with coils or liquid embolics. Crucially, the laser fenestration must be relined with a covered stent or cuff to seal the iatrogenic defect and prevent a type IIIb endoleak. The largest clinical series to date, covering five patients and eleven target vessels, reported a 100 percent technical success rate with no major perioperative complications, and all patients demonstrated stability or regression of aneurysm sac diameter on follow-up imaging. A simpler variant using a long custom needle to puncture the graft fabric under fusion imaging guidance achieved technical success in all 10 patients in a dedicated case series, with nine demonstrating stable or regressing sacs at a mean follow-up of 24 months and no type III endoleaks observed.

The third and perhaps most paradigm-shifting strategy aims to prevent type II endoleaks before they develop. Prophylactic aneurysm sac embolization at the time of EVAR fills the sac with embolic material during the initial procedure, and the most promising tool is the shape memory polymer plug—a porous, self-expanding material that changes shape upon contact with blood or body temperature. Delivered through standard 0.035-inch catheters, the polymer expands slowly, conforming to the aneurysm cavity and creating a scaffold that promotes thrombus formation without relying on coils or liquid agents. In a multicenter prospective study of 35 patients, technical success was 100 percent with no device-related complications, and during a median follow-up of 11 months, significant sac shrinkage was observed in over 85 percent of patients, with no secondary interventions required for type II endoleaks. A separate two-center study of 29 patients reported no perioperative complications, no endoleaks, and no reinterventions, while the majority achieved aneurysm sac regression by both volume and diameter. Because the plugs are biodegradable and produce no imaging artifacts, they may even simplify postoperative surveillance compared with coils or liquid embolics.

Despite the encouraging early results, the review authors are careful to temper enthusiasm. The evidence for all three novel techniques remains largely retrospective, based on case series and small patient cohorts, with heterogeneous outcome definitions and no long-term durability data. The 2024 ESVS guidelines currently recommend against routine pre-emptive embolization of the inferior mesenteric artery, lumbar arteries, or non-selective aneurysm sac embolization because a clinically relevant long-term benefit has not yet been sufficiently demonstrated. Laser-assisted transgraft embolization requires specialized equipment and operator expertise, and the cumulative cost of laser catheters and additional graft material may be significant. Shape memory polymer devices are off-label in many regions and not yet widely reimbursed.

What emerges is a stepwise management strategy grounded in aneurysm sac behavior rather than the presence of a leak alone. Type II endoleaks without significant sac enlargement should generally remain under imaging surveillance, with contrast-enhanced ultrasound increasingly used alongside CT angiography to identify active flow in low-pressure endoleaks without nephrotoxic contrast or radiation. In patients with progressive sac expansion, occult type I or III endoleaks should first be excluded before attributing growth to a type II leak. When intervention is indicated, transarterial embolization and direct sac puncture remain the most established approaches, while transcaval or transgraft access may provide alternatives when conventional routes are technically difficult or have previously failed. Persistent aneurysm growth despite endovascular treatment should prompt reassessment of the endoleak etiology and, in selected surgically fit patients, consideration of open conversion. Larger prospective studies are now essential to determine whether transcaval embolization, laser-assisted transgraft embolization, and prophylactic shape memory polymer embolization can deliver durable reductions in sac expansion, reintervention, and aneurysm-related complications—and to define evidence-based criteria for matching each patient’s anatomy to the right technique.

Subject of Research: Novel embolization techniques for type II endoleaks after EVAR

Article Title: Novel techniques in the prophylaxis and treatment of type II endoleaks: a narrative review

Article References: Pietrzak, K., Koperski, M., Gutowska, K., & Terlecki, P. (2026). Novel techniques in the prophylaxis and treatment of type II endoleaks: a narrative review. Frontiers in Cardiovascular Medicine, 13, Article 1847190. https://doi.org/10.3389/fcvm.2026.1847190

Image Credits: AI Generated

DOI: 10.3389/fcvm.2026.1847190

Keywords: type II endoleak, EVAR, abdominal aortic aneurysm, transcaval embolization, laser-assisted transgraft embolization, shape memory polymer, aneurysm sac embolization, endovascular repair, embolization, vascular surgery, stent graft, aneurysm sac expansion